VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.

Tune in to hear the expert panel offer their perspectives on adjuvant olaparib and the results of the OlympiA trial, capecitabine in the ECOG study, the GeparNuevo trial which looked at adding durvalumab to chemotherapy in patients with TNBC, as well as first-line paclitaxel plus durvalumab for TNBC in the BEGONIA trial. The panel also discuss the latest data for CDK4/6 inhibitors, SERDs and BCL-2 inhibitors, the use of talazoparib in the neoadjuvant setting and much more.